Free report on upcoming FDA panel decision of Corvue on July 28th (Tuesday)

FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by the FDA will increase significantly. If the drug gets approved by the FDA, it is estimated to achieve Peak sales of $350 million. To read about our expectation on the Panel decision, the company, the drug, the disease and the potential impact of this FDA Panel decision next week, get the FREE report at: www.newbiomedicine.com